CRMD stock icon

CorMedix

12.10 USD
+0.50
4.31%
Updated Nov 11, 12:28 PM EST
1 day
4.31%
5 days
26.30%
1 month
19.57%
3 months
232.42%
6 months
128.30%
Year to date
220.95%
1 year
289.07%
5 years
122.02%
10 years
45.78%
 

About: Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.

Employees: 82

0
Funds holding %
of 6,759 funds
0
Analysts bullish %
of 4 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 9

68% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 22

10% more funds holding

Funds holding: 90 [Q1] → 99 (+9) [Q2]

1% more capital invested

Capital invested by funds: $74.9M [Q1] → $75.5M (+$629K) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

0.4% less ownership

Funds ownership: 32.12% [Q1] → 31.72% (-0.4%) [Q2]

80% less call options, than puts

Call options by funds: $305K | Put options by funds: $1.55M

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$10
17%
downside
Avg. target
$14.50
20%
upside
High target
$18
49%
upside

4 analyst ratings

positive
100%
neutral
0%
negative
0%
Needham
Serge Belanger
50% 1-year accuracy
57 / 114 met price target
49%upside
$18
Buy
Maintained
31 Oct 2024
Truist Securities
Joon Lee
64% 1-year accuracy
29 / 45 met price target
41%upside
$17
Buy
Maintained
22 Oct 2024
Rodman & Renshaw
Brandon Folkes
63% 1-year accuracy
5 / 8 met price target
7%upside
$13
Buy
Initiated
26 Aug 2024
Needham
Serge Belanger
50% 1-year accuracy
57 / 114 met price target
17%downside
$10
Buy
Reiterated
15 Aug 2024

Financial journalist opinion

Based on 13 articles about CRMD published over the past 30 days

Charts implemented using Lightweight Charts™